Tresiba shows hypoglycemia benefit in CVOT

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said Tresiba insulin degludec showed superiority to Lantus insulin glargine in preventing severe hypoglycemia in the Phase III DEVOTE cardiovascular outcomes trial. The outcome was a secondary endpoint in DEVOTE.

Novo said 27% fewer Tresiba-treated patients experienced severe hypoglycemia compared to Lantus, with a 40% overall reduction in total episodes of adjudicated severe hypoglycemia. The Tresiba group also had a 54% relative reduction in the rate of nocturnal severe hypoglycemia. Novo said the hypoglycemia measurements were statically significant...